Predictive Role of Coagulation, Fibrinolytic, and Endothelial Markers in Patients with Atrial Fibrillation, Stroke, and Thromboembolism: A Meta-Analysis, Meta-Regression, and Systematic Review

Alexander Weymann; Anton Sabashnikov; Sadeq Ali-Hasan-Al-Saegh; Aron-Frederik Popov; Seyed Jalil Mirhosseini; William L. Baker; Mohammadreza Lotfaliani; Tong Liu; Hamidreza Dehghan; Senol Yavuz; Michel Pompeu Barros de Oliveira Sá; Jae-Sik Jang; Mohamed Zeriouh; Lei Meng; Fabrizio D’Ascenzo; Abhishek J. Deshmukh; Guiseppe Biondi-Zoccai; Pascal M. Dohmen; Hugh Calkins; Integrated Meta-Analysis of Cardiac Cardiac Surgery and Cardiology-Group IMCSC-Group]

doi:10.12659/MSMBR.902558

31 March 2017 : Meta-Analysis

Predictive Role of Coagulation, Fibrinolytic, and Endothelial Markers in Patients with Atrial Fibrillation, Stroke, and Thromboembolism: A Meta-Analysis, Meta-Regression, and Systematic Review

Alexander Weymann^{ABCDEFG 1*}, Anton Sabashnikov^{ABCDEFG 2,3}, Sadeq Ali-Hasan-Al-Saegh^{ABCDEFG 4}, Aron-Frederik Popov^{ABCDEFG 5}, Seyed Jalil Mirhosseini^{ABCDEFG 4}, William L. Baker^{ABCDEFG 6}, Mohammadreza Lotfaliani^{ABCDEFG 4}, Tong Liu^{ABCDEFG 7}, Hamidreza Dehghan^{ABCDEFG 8}, Senol Yavuz^{ABCDEFG 9}, Michel Pompeu Barros de Oliveira Sá^{ABCDEFG 10,11,12}, Jae-Sik Jang^{ABCDEFG 13}, Mohamed Zeriouh^{ABCDEFG 2,3}, Lei Meng^{ABCDEFG 14}, Fabrizio D’Ascenzo^{ABCDEFG 15}, Abhishek J. Deshmukh^{ABCDEFG 16}, Guiseppe Biondi-Zoccai^{ABCDEFG 17,18}, Pascal M. Dohmen^{ABCDEFG 1}, Hugh Calkins^{ABCDEFG 19}, Integrated Meta-Analysis of Cardiac Cardiac Surgery and Cardiology-Group IMCSC-Group]

DOI: 10.12659/MSMBR.902558

Med Sci Monit Basic Res 2017; 23:97-140

Authors information Article notes Copyright and License information

¹Department of Cardiac Surgery, University Hospital Oldenburg, European Medical School Oldenburg-Groningen, Carl von Ossietzky University Oldenburg, Oldenburg, Germany
²Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Harefield Middlesex, United Kingdom
³Department of Cardiothoracic Surgery, University Hospital Cologne, Cologne, Germany
⁴Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
⁵Department of Cardiac Surgery, University Hospital Frankfurt am Main, Frankfurt am Main, Germany
⁶ University of Connecticut/Hartford Hospital Evidence-Based Practice Center, Hartford, USA
⁷Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, 2nd Hospital of Tianjin Medical University, Tianjin, China
⁸Department of Health Technology Assessment, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran
⁹Department of Cardiovascular Surgery, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
¹⁰Division of Cardiovascular Surgery, Pronto Socorro Cardiológico de Pernambuco – PROCAPE, Recife, Brazil
¹¹ Nucleus of Postgraduate and Research in Health Sciences of Faculty of Medical Sciences and Biological Sciences Institute (FCM/ICB), Recife, Brazil
¹² University of Pernambuco – UPE, Recife, Brazil
¹³Department of Cardiology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea
¹⁴Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
¹⁵Mayo Clinic Heart Rhythm Section, Cardiovascular Diseases, Mayo Clinic, Rochester, USA
¹⁶Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy
¹⁷Department of AngioCardioNeurology, IRCCS Neuromed, Pozzilli, Italy
¹⁸Department of Cardiology, Johns Hopkins Medical Institutions, Baltimore, USA

^*Corresponding Author: Alexander Weymann, e-mail: [email protected]

^AStudy design/planning
^BData collection/entry
^CData analysis/statistics
^DData interpretation
^EPreparation of manuscript
^FLiterature analysis/search
^GFunds collection

Related articles Order reprints Share article Share by email

View HTML version

Supplementary Table 2 Extra details of characteristics of each study for exploration of heterogeneity factors.

First Author	Geographic area	Total N	Total age	Total male	Total DM	Total HTN	Total MI	Total diuretic	Total ACEI	Total. statin	Total BB	AC-code	Chronic or not	CS
Negreva []⁹	European	103	59.67	50.45	4.8	68.96	ND	ND	28.165	6.805	34.97	1	Acute	14.5
Amdur []¹⁰	North America	3762	58.9	54.55	49.8	86.7	ND	64.65	69.85	ND	56.1	4	No detection	ND
Yusuf (disease control) []¹¹	Asian	65	31.5	42.85	ND	ND	ND	ND	ND	ND	ND	1	No detection	ND
Yusuf (healthy control) []¹¹	Asian	65	30.055	38.55	ND	ND	ND	ND	ND	ND	ND	1	No detection	ND
Drabik (persistent) []¹²	European	97	60.1	64.95	20	48.85	17.35	ND	52.25	53.15	60.6	4	Acute	22.5
Drabik (PAF) []¹²	European	91	60	55.15	16.4	46.05	26.65	ND	54.05	47.45	57.25	4	Acute	20
Borgi []¹³	Africa	69	ND	ND	ND	ND	ND	ND	ND	ND	ND	5	No detection	ND
Oneal (with comorbidities) []¹⁴	North America	647	69.5	54	32.5	70	ND	ND	ND	29.5	ND	4	No detection	15
Oneal (with comorbidities) []¹⁴	North America	883	64.5	32.5	29.5	54.5	ND	ND	ND	30	ND	4	No detection	14
Erdogan []¹⁵	European	67	69.55	49.275	10	65	ND	18	53.5	ND	43.3	3	Chronic	6
Chen (without comorbidities) []¹⁶	Asian	162	53.695	61.03	15	31.5	ND	ND	ND	ND	ND	4	Acute	ND
Chen (with comorbidities) []¹⁶	Asian	207	55.845	64.2	13.5	35.5	ND	ND	ND	ND	ND	4	Acute	ND
Schnabel []¹⁷	European	4998	60.05	54.5	10.15	61.95	8.3	ND	ND	ND	ND	5	No detection	15.3
Wei-Hong Ma []¹⁸	Asian	105	58	72.25	0	100	ND	ND	ND	ND	ND	2	No detection	ND
Xu (without comorbidities) []¹⁹	Asian	115	66.85	50.45	37.4	53.1	ND	ND	42.6	29.55	43.55	4	Chronic	38.5
Xu (with comorbidities) []¹⁹	Asian	115	67.975	51.3	36.5	57.5	ND	ND	40.8	26.05	40.95	4	Chronic	31.2
Distelmaier []²⁰	North America	198	73.5	61	24	60.5	25	ND	ND	ND	ND	5	Acute	ND
Scridon (PAF) []²¹	European	69	55.5	78.5	7	39.5	ND	ND	18.5	13.5	ND	3	Acute	13
Scridon (persistent) []²¹	European	53	55	78.5	7	35.5	ND	ND	24	15.5	ND	3	Acute	13
Berge []²²	European	189	75	71	8	48	ND	19	21	34.5	28	4	No detection	ND
Acevedo []²³	South America	150	ND	ND	ND	ND	ND	ND	ND	ND	ND	1	No detection	ND
Zorlu []²⁴	European	150	69.5	62	16	33	ND	ND	75.5	ND	76	1	No detection	ND
Alonso (White) []²⁵	North America	11107	55.7	52.25	12.05	34.85	6.6	ND	ND	ND	ND	1	No detection	26.7
Alonso (African-American) []²⁵	North America	3751	54.8	41.2	26.05	63.65	ND	ND	ND	ND	ND	1	No detection	32
Adamsson Eryd []²⁶	European	6031	47.25	100	4.8	6	ND	ND	ND	ND		5	No detection	48
Fu []²⁷	Asian	169	54.45	63.5	ND	ND	ND	ND	ND	12.9	6.1	4	No detection	42.5
Hou (disease control) []²⁸	Asian	52	64.85	57.6	0	ND	ND	ND	40.35	ND	11.45	4	Acute	26.9
Hou (healthy control) []²⁸	Asian	52	65.3	57.6	0	ND	ND	ND	21.15	ND	7.65	4	Acute	26.9
Schnabel []²⁹	North America	3120	62.05	52.5	ND	38	ND	ND	ND	ND	ND	5	No detection	ND
Letsas (PAF) []³⁰	European	93	64.4	59	6	60.5	ND	ND	43	15.5	34	5	acute	ND
Letsas (permanent) []³⁰	European	89	66.6	59.5	11	63	ND	ND	52.5	13.5	35.5	5	chronic	ND
Gartner []³¹	Australia	250	59.45	65.5	9	48.5	ND	ND	ND	ND	ND	4	No detection	ND
Targonski (PAF and PeAF) []³²	European	56	63.5	67.7	44.75	69.6	ND	67.7	96.65	87.3	85.4	4		12.4
Targonski (Permanent) []³²	European	73	69.3	66.4	33.3	72.2	ND	78.05	90.85	70.6	89.2	4		11.3
Marcus []³³	North America	971	70	87.5	22.5	65.5	52	ND	57	59.5	ND	5	No detection	15
Blann []³⁴	European	82	64.5	62.75	ND	27	ND	16.5	19	ND	18.5	3	No detection	12.6
Topaloglu (disease control) []³⁵	European	46	34.5	ND	0	0	ND	ND	ND	ND	ND	5	No detection	ND
Topaloglu (healthy control) []³⁵	European	38	36	ND	0	0	ND	ND	ND	ND	ND	5	No detection	ND
Cecchi (with cerebral ischemic) []³⁶	European	192	73.5	60.2	7.25	45.95	ND	18.05	27.3	6.85	6.8	3	No detection	30.1
Cecchi (without cerebral ischemic) []³⁶	European	224	73	59.35	6.4	47.5	ND	20.5	27.05	7.3	8.05	3	No detection	25.9
Turgut (disease control) []³⁷	European	55	66.11	44.7	17.4	67.6	ND	ND	ND	ND	ND	4	No detection	ND
Turgut (healthy control) []³⁷	European	46	66.56	43.95	3.85	36.55	ND	ND	ND	ND	ND	4	No detection	ND
Heeringa []³⁸	European	486	77.5	51	17.5	25	22.5	31.65	ND	ND	16.55	5	No detection	20.9
Roldan []³⁹	European	265	ND	ND	ND	ND	ND	ND	ND	ND	ND	4	No detection	ND
Marin (acute AF) []⁴⁰	European	48	63.5	50	0	8.3	8.3	ND	10.4	ND	8.3	4	Acute	ND
Marin (chronic AF) []⁴⁰	European	48	63.5	47.9	14.55	12.5	6.25	ND	6.25	ND	4.15	4	Chronic	ND
Inoue (with comorbidities) []⁴¹	Asian	251	ND	ND	ND	ND	ND	ND	ND	ND	ND	5	No detection	ND
Inoue (Lone AF) []⁴¹	Asian	106	ND	ND	ND	ND	ND	ND	ND	ND	ND	5	No detection	ND
Conway []⁴²	European	147	68	62	7.5	26.5	13.5	ND	ND	ND	ND	3	chronic	16
Hatzinikolaou-Kotsakou (PAF) []⁴³	European	35	59	77.25	8.3	13.85	13.85	ND	ND	ND	ND	5	Acute	20.5
Hatzinikolaou-Kotsakou (persistent) []⁴³	European	34	60	73.5	5.85	20.585	17.6	ND	ND	ND	ND	5	Acute	20.8
Hatzinikolaou-Kotsakou (permanent) []⁴³	European	37	61.5	76.15	5	22.5	15	ND	ND	ND	ND	5	Chronic	24.2
Conway []⁴⁴	European	74	67.5	70.2	9.45	27	1.35	ND	ND	ND	ND	5	Acute	11.2
Kamath (PAF and PeAF) []⁴⁵	European	62	63.5	51.6	ND	ND	ND	ND	ND	ND	ND	1	Acute	ND
Kamath (permanent AF) []⁴⁵	European	124	66	52.65	ND	ND	ND	ND	ND	ND	ND	1	Chronic	ND
Marin []⁴⁶	European	80	70.5	55	19.5	52	6.5	ND	ND	ND	4	4	Chronic	ND
Conway []⁴⁷	European	486	77.5	51.05	8.3	10.595	8.6	ND	ND	ND	ND	1	No detection	10.3
Kamath (PAF) []⁴⁸	European	58	63	48.235	6.85	24.1	3.4	ND	ND	ND	ND	4	Acute	5.1
Kamath (permanent AF) []⁴⁸	European	116	65	52.25	5.15	30.45	6.85	ND	ND	ND	ND	4	Chronic	5.1
Kamath []⁴⁹	European	143	70	63.2	ND	ND	ND	ND	ND	ND	ND	1	No detection	5.9
Wang []⁵⁰	Asian	3212	60	51.65	23.65	40.6	3.65	ND	ND	ND	ND	5	No detection	32.6
Li-saw-Hee (PAF) []⁵¹	European	43	64	77.3	2.15	10.85	6.5	ND	ND	ND	ND	3	Acute	13.4
Li-saw-Hee (PeAF) []⁵¹	European	43	64	77.25	2.15	13	4.3	ND	ND	ND	ND	3	Acute	11.5
Li-saw-Hee (permanent) []⁵¹	European	43	65	77.25	6.52	23.9	15.2	ND	ND	ND	ND	3	Chronic	11.5
Feng []⁵²	North America	214	62.15	73.5	12.85	36	23.25	ND	ND	ND	ND	6	No detection	16.1
Topcuoglu []⁵³	European	36	62.35	61.87	13.5	42.5	ND	ND	ND	ND	ND	1	No detection	20
Mondillo []⁵⁴	European	80	66.95	82.85	ND	ND	ND	ND	ND	ND	ND	3	Chronic	33.7
Giansante []⁵⁵	European	105	63.5	55.67	8.5	29.25	ND	ND	ND	ND	ND	1	Acute	35.6
Li-saw-Hee []⁵⁶	European	112	67	77.5	3.85	12.5	11.55	ND	ND	ND	ND	1	Chronic	13.3
Marin (disease control) []⁵⁷	European	42	53.5	17.35	0	ND	ND	ND	ND	ND	ND	1	No detection	ND
Marin (healthy control) []⁵⁷	European	38	ND	ND	0	ND	ND	ND	ND	ND	ND	1	No detection	ND
Li-saw-Hee []⁵⁸	European	50	59	20	ND	ND	ND	ND	ND	ND	ND	5	Chronic	20
Roldan []⁵⁹	European	56	62	ND	0	ND	ND	ND	ND	ND	ND	1	Chronic	ND
Tsai []⁵⁰	Asian	111	64	74.45	ND	ND	ND	ND	ND	ND	ND	4	Chronic	ND
Minamino []⁶¹	Asian	90	63	73.3	12.5	23.5	ND	ND	ND	ND	14.5	5	Chronic	ND
Kahn []⁶²	North America	81	ND	ND	ND	ND	ND	ND	ND	ND	ND	1	Chronic	ND
Sohara []⁶³	Asian	30	59.1	ND	ND	ND	ND	ND	ND	ND	ND	1	Acute	ND
Lip (PAF)[]⁶⁴	European	188	59.85	57.8	ND	ND	ND	ND	ND	ND	ND	1	Acute	30
Lip (chronic) []⁶⁴	European	214	61.8	56.37	ND	ND	ND	ND	ND	ND	ND	1	Chronic	33
Lip []⁶⁵	European	77	ND	ND	ND	ND	ND	ND	ND	ND	ND	1	Chronic	ND
Mitusch []⁶⁶	European	97	71	51.35	25	67	ND	ND	ND	ND	ND	1	No detection	ND
Nagao []⁶⁷	Asian	36	79.95	44.575	ND	ND	ND	ND	ND	ND	ND	1	No detection	ND
Lip []⁶⁸	European	245	61.15	53.3	ND	ND	ND	ND	ND	ND	ND	5	Chronic	ND
Sohara []⁶⁹	Asian	22	ND	ND	ND	ND	ND	ND	ND	ND	ND	1	Acute	ND
Kumagai []⁷⁰	Asian	94	62.5	48.15	ND	ND	ND	ND	ND	ND	ND	1	Chronic	ND
Gustafsson (with stroke) []⁷¹	European	60	77	ND	ND	ND	ND	ND	ND	ND	ND	1	No detection	30
Gustafsson (without stroke) []⁷¹	European	60	77	ND	ND	ND	ND	ND	ND	ND	ND	1	No detection	25

Back to the Article

Predictive Role of Coagulation, Fibrinolytic, and Endothelial Markers in Patients with Atrial Fibrillation, Stroke, and Thromboembolism: A Meta-Analysis, Meta-Regression, and Systematic Review

Your Privacy